Do analysts rate LNAI or CING?

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 474.23%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings & valuation, LNAI or CING?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Cingulate N/A N/A -$22.45M -$4.23 N/A

Is LNAI or CING more profitable?

Cingulate's return on equity of -365.15% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Cingulate N/A -365.15% -158.55%

Do analysts recommend LNAI or ACRV?

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 638.40%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acrivon Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has stronger valuation and earnings, LNAI or ACRV?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Acrivon Therapeutics N/A N/A -$77.90M -$2.00 N/A

Is LNAI or ACRV more profitable?

Acrivon Therapeutics' return on equity of -64.43% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Acrivon Therapeutics N/A -64.43% -57.08%

Do analysts recommend KALA or LNAI?

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 39,850.98%. Given KALA BIO's stronger consensus rating and higher probable upside, equities research analysts plainly believe KALA BIO is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KALA BIO 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, KALA or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio KALA BIO N/A N/A -$26.98M -$96.14 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is KALA or LNAI more profitable?

Lunai Bioworks' return on equity of -1,243.45% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets KALA BIO N/A -1,336.10% -94.85% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts recommend LNAI or EXOZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% eXoZymes N/A -220.63% -141.26%

Do analysts recommend BYSI or LNAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BYSI or LNAI more profitable?

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -14.00% Lunai Bioworks N/A -1,243.45% -1,617.76%

Lunai Bioworks (LNAI) Competitors

$3.56 +0.13 (+3.79%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$3.36 -0.20 (-5.62%)

As of 04:26 AM Eastern

Compare

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include Cingulate (CING), Acrivon Therapeutics (ACRV), KALA BIO (KALA), eXoZymes (EXOZ), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical products" industry.

How does Lunai Bioworks compare to Cingulate?

Lunai Bioworks (NASDAQ:LNAI) and Cingulate (NASDAQ:CING) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 5.3% of Cingulate shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cingulate has a consensus price target of $27.33, suggesting a potential upside of 474.23%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Lunai Bioworks has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A

In the previous week, Cingulate had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for Lunai Bioworks. Cingulate's average media sentiment score of 1.33 beat Lunai Bioworks' score of 0.00 indicating that Cingulate is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Cingulate	Positive

Cingulate's return on equity of -365.15% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Cingulate	N/A	-365.15%	-158.55%

Summary

Cingulate beats Lunai Bioworks on 10 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Acrivon Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 10.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Acrivon Therapeutics' return on equity of -64.43% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Acrivon Therapeutics	N/A	-64.43%	-57.08%

Acrivon Therapeutics has a consensus price target of $11.67, suggesting a potential upside of 638.40%. Given Acrivon Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Acrivon Therapeutics is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acrivon Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Lunai Bioworks is trading at a lower price-to-earnings ratio than Acrivon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Acrivon Therapeutics	N/A	N/A	-$77.90M	-$2.00	N/A

Lunai Bioworks has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market. Comparatively, Acrivon Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. Acrivon Therapeutics' average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
Acrivon Therapeutics	Very Positive

Summary

Acrivon Therapeutics beats Lunai Bioworks on 11 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to KALA BIO?

KALA BIO (NASDAQ:KALA) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

24.6% of KALA BIO shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 2.2% of KALA BIO shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lunai Bioworks is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, KALA BIO and KALA BIO both had 1 articles in the media. KALA BIO's average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that KALA BIO is being referred to more favorably in the media.

Company	Overall Sentiment
KALA BIO	Very Positive
Lunai Bioworks	Neutral

KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

KALA BIO currently has a consensus target price of $1,018.75, suggesting a potential upside of 39,850.98%. Given KALA BIO's stronger consensus rating and higher probable upside, equities research analysts plainly believe KALA BIO is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lunai Bioworks' return on equity of -1,243.45% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
KALA BIO	N/A	-1,336.10%	-94.85%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Summary

KALA BIO beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks.

How does Lunai Bioworks compare to eXoZymes?

Lunai Bioworks (NASDAQ:LNAI) and eXoZymes (NASDAQ:EXOZ) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Lunai Bioworks has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.65, meaning that its share price is 165% more volatile than the broader market.

eXoZymes' return on equity of -220.63% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
eXoZymes	N/A	-220.63%	-141.26%

71.4% of Lunai Bioworks shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

eXoZymes has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
eXoZymes	$70K	896.46	-$9.16M	-$1.14	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Lunai Bioworks and Lunai Bioworks both had 1 articles in the media. eXoZymes' average media sentiment score of 0.93 beat Lunai Bioworks' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Neutral
eXoZymes	Positive

Summary

eXoZymes beats Lunai Bioworks on 8 of the 10 factors compared between the two stocks.

How does Lunai Bioworks compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

In the previous week, BeyondSpring and BeyondSpring both had 1 articles in the media. BeyondSpring's average media sentiment score of 1.87 beat Lunai Bioworks' score of 0.00 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Lunai Bioworks	Neutral

BeyondSpring has higher revenue and earnings than Lunai Bioworks. BeyondSpring is trading at a lower price-to-earnings ratio than Lunai Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	37.60	-$1.01M	-$0.14	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

BeyondSpring has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

BeyondSpring's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-14.00%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

40.3% of BeyondSpring shares are owned by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are owned by institutional investors. 29.3% of BeyondSpring shares are owned by insiders. Comparatively, 0.5% of Lunai Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

BeyondSpring beats Lunai Bioworks on 8 of the 10 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$15.55M	$777.78M	$4.33B	$12.27B
Dividend Yield	N/A	4.84%	11.45%	5.88%
P/E Ratio	-8.90	1.43	21.93	23.97
Price / Sales	N/A	118.23	154.39	99.72
Price / Cash	N/A	20.06	38.01	53.91
Price / Book	-0.36	7.95	14.74	6.32
Net Income	-$178.01M	-$4.05M	$115.37M	$337.22M
7 Day Performance	-5.82%	-0.26%	-1.64%	-1.23%
1 Month Performance	68.72%	0.56%	-2.83%	-0.63%
1 Year Performance	N/A	45.81%	11.31%	27.95%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.1955 of 5 stars	$3.56 +3.8%	N/A	N/A	$15.55M	N/A	N/A	20	Positive News
CING Cingulate	3.6177 of 5 stars	$5.01 +0.3%	$27.33 +446.0%	+15.8%	$67.21M	N/A	N/A	20	Positive News
ACRV Acrivon Therapeutics	1.7405 of 5 stars	$1.57 flat	$11.67 +643.1%	+18.8%	$67.20M	N/A	N/A	58	Positive News
KALA KALA BIO	2.5195 of 5 stars	$3.61 flat	$1,018.75 +28,120.2%	-98.9%	$67.11M	N/A	N/A	30	Positive News High Trading Volume
EXOZ eXoZymes	0.4726 of 5 stars	$7.83 flat	N/A	-27.7%	$66.39M	$70K	N/A	29	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

How does Lunai Bioworks compare to Cingulate?

Summary

How does Lunai Bioworks compare to Acrivon Therapeutics?

Summary

How does Lunai Bioworks compare to KALA BIO?

Summary

How does Lunai Bioworks compare to eXoZymes?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. CING, ACRV, KALA, EXOZ, and BYSI

How does Lunai Bioworks compare to Cingulate?

Do insiders and institutionals have more ownership in LNAI or CING?

Do analysts rate LNAI or CING?

Which has more volatility and risk, LNAI or CING?

Which has stronger earnings & valuation, LNAI or CING?

Does the media refer more to LNAI or CING?

Is LNAI or CING more profitable?

Summary

How does Lunai Bioworks compare to Acrivon Therapeutics?

Do institutionals and insiders hold more shares of LNAI or ACRV?

Is LNAI or ACRV more profitable?

Do analysts recommend LNAI or ACRV?

Which has stronger valuation and earnings, LNAI or ACRV?

Which has more volatility & risk, LNAI or ACRV?

Does the media favor LNAI or ACRV?

Summary

How does Lunai Bioworks compare to KALA BIO?

Do institutionals & insiders have more ownership in KALA or LNAI?

Which has preferable earnings & valuation, KALA or LNAI?

Does the media prefer KALA or LNAI?

Which has more volatility and risk, KALA or LNAI?

Do analysts recommend KALA or LNAI?

Is KALA or LNAI more profitable?

Summary

How does Lunai Bioworks compare to eXoZymes?

Which has more volatility & risk, LNAI or EXOZ?

Is LNAI or EXOZ more profitable?

Do institutionals and insiders hold more shares of LNAI or EXOZ?

Which has preferable valuation and earnings, LNAI or EXOZ?

Do analysts recommend LNAI or EXOZ?

Does the media refer more to LNAI or EXOZ?

Summary

How does Lunai Bioworks compare to BeyondSpring?

Does the media prefer BYSI or LNAI?

Which has higher earnings & valuation, BYSI or LNAI?

Which has more risk and volatility, BYSI or LNAI?

Is BYSI or LNAI more profitable?

Do analysts recommend BYSI or LNAI?

Do institutionals & insiders believe in BYSI or LNAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools